#United States #StimLabs #Geistlich #regenerative medicine #Roswell

StimLabs and Geistlich Expand Their Partnership

In January 2026, StimLabs announced an exciting development in the field of regenerative medicine through an expanded partnership with Geistlich, a renowned global leader in this sector. The two companies have been working together since 2024 when they formed an exclusive national distribution agreement centered around a revolutionary line of wound care products. This collaboration initially focused on the advanced wound matrix, Derma-Gide®, and is now moving towards a novel wound care product set to be released in the second quarter of 2026.

John Daniel, the Founder and CEO of StimLabs, expressed enthusiasm about the partnership, stating, "Geistlich has continued to demonstrate their skill in innovation and commitment to quality, which are core values at StimLabs. We look forward to working with them to bring another unique solution to our patients and providers." This sentiment was echoed by StimLabs EVP and Chief Commercial Officer, Tom Dion, who emphasized the potential longevity and success of the partnership.

Diego Gabathuler, CEO of Geistlich, highlighted their mission stating, "At Geistlich, our mission is to restore quality of life through regenerative solutions. We believe in combining scientific excellence with clinical trust to deliver innovations that truly make a difference for patients worldwide." This reveals the deep-rooted commitment both companies have toward advancing healthcare and enhancing the quality of life for patients.

The foundation of this partnership is underpinned by the immense expertise each company contributes. David Wemans, VP of Regenerative Technologies at Geistlich, spoke about the synergies between the two entities, noting, "By leveraging our research innovation with StimLabs' commercial strength, this partnership is poised to set new standards in regenerative medicine." The collective resources and knowledge from both StimLabs and Geistlich position them well to revolutionize wound care, particularly in areas where there are unmet clinical needs.

About StimLabs

StimLabs is recognized as a pioneering company in the domain of regenerative medicine, with a strong focus on wound care and surgical applications. Their commitment to providing patients with optimal care while addressing urgent clinical needs has been exemplary. With a vast product portfolio and a robust catalog of intellectual properties, the company stands as a trusted partner for healthcare providers and patients alike.

About Geistlich

On the other hand, Geistlich boasts a rich 175-year history in regenerative medicine. The Swiss family-owned business emphasizes high-quality manufacturing, offering comprehensive support to clinicians through scientific research and education. With a global presence that spans approximately 90 markets, Geistlich employs over 800 professionals committed to advancing the field of regenerative medicine, reaffirming their position as a frontrunner in the industry.

As StimLabs and Geistlich forge ahead in their partnership, the medical community and patients alike eagerly await the launch of their new wound care product in Q2 2026, anticipating advancements that will not only improve healthcare outcomes but also enhance patient experiences significantly.